Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/107371
DC FieldValueLanguage
dc.contributor.authorMoura, João-
dc.contributor.authorSørensen, Anja-
dc.contributor.authorLeal, Ermelindo-
dc.contributor.authorSvendsen, Rikke-
dc.contributor.authorCarvalho, Lina-
dc.contributor.authorWillemoes, Rie Juul-
dc.contributor.authorJørgensen, Per Trolle-
dc.contributor.authorJenssen, Håvard-
dc.contributor.authorWengel, Jesper-
dc.contributor.authorDalgaard, Louise Torp-
dc.contributor.authorCarvalho, Eugenia-
dc.date.accessioned2023-07-06T10:22:38Z-
dc.date.available2023-07-06T10:22:38Z-
dc.date.issued2019-04-09-
dc.identifier.issn2045-2322pt
dc.identifier.urihttps://hdl.handle.net/10316/107371-
dc.description.abstractTreatment for chronic diabetic foot ulcers is limited by the inability to simultaneously address the excessive inflammation and impaired re-epithelization and remodeling. Impaired re-epithelization leads to significantly delayed wound closure and excessive inflammation causes tissue destruction, both enhancing wound pathogen colonization. Among many differentially expressed microRNAs, miR-155 is significantly upregulated and fibroblast growth factor 7 (FGF7) mRNA (target of miR-155) and protein are suppressed in diabetic skin, when compared to controls, leading us to hypothesize that topical miR-155 inhibition would improve diabetic wound healing by restoring FGF7 expression. In vitro inhibition of miR-155 increased human keratinocyte scratch closure and topical inhibition of miR-155 in vivo in wounds increased murine FGF7 protein expression and significantly enhanced diabetic wound healing. Moreover, we show that miR-155 inhibition leads to a reduction in wound inflammation, in accordance with known pro-inflammatory actions of miR-155. Our results demonstrate, for the first time, that topical miR-155 inhibition increases diabetic wound fibroblast growth factor 7 expression in diabetic wounds, which, in turn, increases re-epithelization and, consequently, accelerates wound closure. Topical miR-155 inhibition targets both excessive inflammation and impaired re-epithelization and remodeling, being a potentially new and effective treatment for chronic diabetic foot ulcers.pt
dc.language.isoengpt
dc.publisherSpringer Naturept
dc.relationJM acknowledges a postdoctoral fellowship from the HealthyAging2020 project, CENTRO-01-0145-FEDER- 000012-N2323. ECL acknowledges a postdoctoral fellowship from the Portuguese Foundation for Science and Technology, SFRH/BPD/112883/2015. AES acknowledges a post doctoral fellowship from the Danish Diabetes Academy, supported by the Novo Nordisk Foundation. The authors would like to thank Christa Persson for dedicated and skilled technical expertise. This work was supported by the European Foundation for the Study of Diabetes to LTD, HJ and EC, the Danish Medical Research Council to LTD, GIFT/SPD to EC, HealthyAging2020 CENTRO-01-0145-FEDER-000012-N2323 to EC, as well as Pepper grant: P30 AG028718 and NIGMS_NIH P20GM109096pt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subject.meshAnimalspt
dc.subject.meshDiabetes Mellitus, Experimentalpt
dc.subject.meshDiabetic Footpt
dc.subject.meshFibroblast Growth Factor 7pt
dc.subject.meshHumanspt
dc.subject.meshKeratinocytespt
dc.subject.meshMalept
dc.subject.meshMicept
dc.subject.meshMicroRNAspt
dc.subject.meshRe-Epithelializationpt
dc.subject.meshWound Healingpt
dc.subject.meshUp-Regulationpt
dc.titlemicroRNA-155 inhibition restores Fibroblast Growth Factor 7 expression in diabetic skin and decreases wound inflammationpt
dc.typearticle-
degois.publication.firstPage5836pt
degois.publication.issue1pt
degois.publication.titleScientific Reportspt
dc.peerreviewedyespt
dc.identifier.doi10.1038/s41598-019-42309-4pt
degois.publication.volume9pt
dc.date.embargo2019-04-09*
uc.date.periodoEmbargo0pt
item.cerifentitytypePublications-
item.languageiso639-1en-
item.fulltextCom Texto completo-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypearticle-
crisitem.author.researchunitiNOVA4Health - Programme in Translational Medicine (iBET, CEDOC/FCM, IPOLFG and ITQB)-
crisitem.author.orcid0000-0003-1748-9861-
crisitem.author.orcid0000-0001-8349-4488-
crisitem.author.orcid0000-0001-6264-3632-
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
I&D CNC - Artigos em Revistas Internacionais
Show simple item record

SCOPUSTM   
Citations

44
checked on May 6, 2024

WEB OF SCIENCETM
Citations

46
checked on May 2, 2024

Page view(s)

66
checked on May 21, 2024

Download(s)

26
checked on May 21, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons